Zacks: Brokerages Anticipate Viracta Therapeutics, Inc. (NASDAQ:VIRX) to Post -$0.32 Earnings Per Share

Brokerages predict that Viracta Therapeutics, Inc. (NASDAQ:VIRX – Get Rating) will announce earnings per share (EPS) of ($0.32) for the current quarter, Zacks reports. Zero analysts have made estimates for Viracta Therapeutics’ earnings, with estimates ranging from ($0.32) to ($0.31). Viracta Therapeutics reported earnings per share of $0.38 in the same quarter last year, which suggests a negative year-over-year growth rate of 184.2%. The firm is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Viracta Therapeutics will report full year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.33). For the next year, analysts anticipate that the business will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.85) to ($1.45). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Viracta Therapeutics.

Viracta Therapeutics (NASDAQ:VIRX – Get Rating) last announced its quarterly earnings data on Wednesday, March 16th. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.09.

Several equities research analysts have weighed in on VIRX shares. Royal Bank of Canada started coverage on shares of Viracta Therapeutics in a report on Tuesday, February 1st. They issued an “outperform” rating and a $10.00 target price on the stock. Zacks Investment Research raised shares of Viracta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 13th.

VIRX traded up $0.01 during mid-day trading on Thursday, hitting $3.31. The stock had a trading volume of 5,102 shares, compared to its average volume of 294,095. The business’s fifty day simple moving average is $3.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.59 and a quick ratio of 11.59. The firm has a market cap of $124.08 million, a price-to-earnings ratio of -0.53 and a beta of 2.26. Viracta Therapeutics has a 1-year low of $2.18 and a 1-year high of $13.08.

In other news, CEO Ivor Royston sold 14,635 shares of the stock in a transaction on Monday, February 28th. The shares were sold at an average price of $2.78, for a total transaction of $40,685.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 21,028 shares of company stock valued at $58,458 in the last three months. 3.72% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. grew its position in Viracta Therapeutics by 109.6% in the third quarter. Citigroup Inc. now owns 4,206 shares of the company’s stock valued at $34,000 after purchasing an additional 2,199 shares in the last quarter. Advisor Group Holdings Inc. bought a new position in Viracta Therapeutics in the third quarter valued at $39,000. Bank of New York Mellon Corp grew its position in Viracta Therapeutics by 9.8% in the third quarter. Bank of New York Mellon Corp now owns 107,938 shares of the company’s stock valued at $866,000 after purchasing an additional 9,643 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in Viracta Therapeutics in the third quarter valued at $81,000. Finally, Invesco Ltd. bought a new position in Viracta Therapeutics in the third quarter valued at $94,000. 42.12% of the stock is owned by institutional investors and hedge funds.

Viracta Therapeutics Company Profile (Get Rating)

Viracta Therapeutics, Inc, a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

Read More